Test your knowledge of CAR T-associated HLH following dual-targeted CAR T-cell therapy

Per American Society for Transplantation and Cellular Therapy recommendations, which of the following would be appropriate for the management of grade 2 CAR T-associated HLH?
Anakinra 100 mg subcutaneously twice daily and intravenous dexamethasone 10 mg daily
Tocilizumab 8 mg/kg intravenously every 8 hours as monotherapy
Etoposide 150 mg/m² intravenously twice weekly without corticosteroids
Intravenous immune globulin 1 g/kg daily for 2 days with prednisone 5 mg daily
Clinical manifestations of IEC-HS can include all of the following except:
Marked hyperferritinemia
Refractory cytopenias
Isolated hypertension without inflammatory markers elevation
Persistent fevers despite CRS-directed therapy
True or false: If a patient’s CRS symptoms are improving, then there should be no concern for HLH.
True
False
Which of the following is important in the management of IEC-HS?
Serial monitoring of ferritin and liver function tests after CRS
Prompt escalation of immunosuppressive therapy when inflammatory markers worsen
The use of ASTCT guidance to support management decisions in severe IEC-HS
All of the above
0
{"name":"Test your knowledge of CAR T-associated HLH following dual-targeted CAR T-cell therapy", "url":"https://www.poll-maker.com/QMFGKHJR3","txt":"Per American Society for Transplantation and Cellular Therapy recommendations, which of the following would be appropriate for the management of grade 2 CAR T-associated HLH?, Clinical manifestations of IEC-HS can include all of the following except:, True or false: If a patient’s CRS symptoms are improving, then there should be no concern for HLH.","img":"https://www.poll-maker.com/3012/images/ogquiz.png"}
Tools: Poll Maker | Quiz Maker